Crestwood Advisors Group LLC Purchases 408 Shares of CVS Health Co. (NYSE:CVS)

Crestwood Advisors Group LLC raised its position in CVS Health Co. (NYSE:CVS) by 2.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 19,380 shares of the pharmacy operator’s stock after buying an additional 408 shares during the period. Crestwood Advisors Group LLC’s holdings in CVS Health were worth $870,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the company. Integrated Advisors Network LLC boosted its position in shares of CVS Health by 0.7% in the 3rd quarter. Integrated Advisors Network LLC now owns 27,625 shares of the pharmacy operator’s stock worth $1,737,000 after purchasing an additional 200 shares during the last quarter. Widmann Financial Services Inc. raised its stake in CVS Health by 1.8% during the 3rd quarter. Widmann Financial Services Inc. now owns 11,506 shares of the pharmacy operator’s stock worth $724,000 after buying an additional 200 shares during the period. Manchester Capital Management LLC raised its stake in CVS Health by 4.8% during the 4th quarter. Manchester Capital Management LLC now owns 4,457 shares of the pharmacy operator’s stock worth $200,000 after buying an additional 204 shares during the period. Rogco LP lifted its holdings in shares of CVS Health by 3.2% in the fourth quarter. Rogco LP now owns 6,752 shares of the pharmacy operator’s stock valued at $303,000 after purchasing an additional 210 shares in the last quarter. Finally, United Asset Strategies Inc. lifted its holdings in shares of CVS Health by 2.4% in the third quarter. United Asset Strategies Inc. now owns 9,217 shares of the pharmacy operator’s stock valued at $580,000 after purchasing an additional 212 shares in the last quarter. 80.66% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Michael F. Mahoney bought 30,000 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were purchased at an average price of $66.70 per share, with a total value of $2,001,000.00. Following the transaction, the director now directly owns 39,356 shares in the company, valued at $2,625,045.20. This represents a 320.65 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.24% of the stock is currently owned by company insiders.

CVS Health Stock Up 1.0 %

Shares of NYSE:CVS opened at $63.65 on Wednesday. The firm has a market cap of $80.24 billion, a P/E ratio of 17.39, a P/E/G ratio of 0.98 and a beta of 0.61. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80. CVS Health Co. has a 12-month low of $43.56 and a 12-month high of $80.75. The business has a fifty day simple moving average of $53.11 and a 200 day simple moving average of $56.29.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, topping analysts’ consensus estimates of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. Analysts predict that CVS Health Co. will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Thursday, January 23rd were paid a $0.665 dividend. The ex-dividend date of this dividend was Thursday, January 23rd. This represents a $2.66 annualized dividend and a dividend yield of 4.18%. CVS Health’s dividend payout ratio is presently 72.68%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on CVS. Barclays boosted their price target on CVS Health from $71.00 to $73.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. Piper Sandler decreased their target price on CVS Health from $72.00 to $64.00 and set an “overweight” rating on the stock in a research report on Monday, November 25th. Deutsche Bank Aktiengesellschaft raised CVS Health from a “hold” rating to a “buy” rating and set a $66.00 price target on the stock in a research report on Tuesday, December 3rd. StockNews.com raised CVS Health from a “sell” rating to a “hold” rating in a research report on Thursday, February 13th. Finally, Leerink Partnrs upgraded CVS Health from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 12th. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $70.00.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.